This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Paxil | |
|---|---|
| Name | Paxil |
| Tradename | Paxil |
| Other names | paroxetine |
| Routes of administration | Oral |
| Class | Selective serotonin reuptake inhibitor |
| Legal status | Prescription-only |
Paxil is a prescription antidepressant belonging to the class of selective serotonin reuptake inhibitors. It is indicated for several mood and anxiety disorders and has been the subject of regulatory review, clinical research, and media attention. Use and safety profiles have been informed by trials, postmarketing surveillance, and litigation involving pharmaceutical companies, regulatory agencies, and patient advocacy groups.
Paxil is approved for major depressive disorder, generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder in various national formularies and by agencies such as the Food and Drug Administration, European Medicines Agency, and national health services of countries like United Kingdom and Australia. Clinical trials published in journals associated with institutions such as Harvard Medical School, Johns Hopkins University, Mayo Clinic, and Stanford University evaluated efficacy against comparators including tricyclics studied at centers like Massachusetts General Hospital and atypical agents researched at Columbia University. Treatment guidelines from organizations such as the American Psychiatric Association, National Institute for Health and Care Excellence, and World Health Organization reference paroxetine among first- or second-line options depending on disorder subtype and patient profile. Off-label uses have been documented in specialist clinics at institutions like Cleveland Clinic and case series reported at university hospitals including University of California, San Francisco and Mount Sinai Hospital.
Contraindications include concomitant use with monoamine oxidase inhibitors approved by regulators like the FDA and agents listed in pharmacopoeias of regions overseen by European Commission health committees. Special populations under surveillance include pregnant individuals monitored by registries such as those affiliated with Centers for Disease Control and Prevention and perinatal psychiatry groups at University College London and King's College London. Caution is advised in patients with bipolar disorder evaluated at centers like Yale School of Medicine and University of Pennsylvania, where mood switching and suicidal ideation concerns mirror findings from multisite cohorts coordinated with institutions such as NIH. Hepatic impairment guidance appears in formularies compiled by agencies like the British Pharmacopoeia and national drug safety advisories from authorities such as Health Canada.
Adverse effect profiles were characterized in multicenter trials conducted by investigators affiliated with Oxford University, Cambridge University, University of Toronto, and research networks linked to Vanderbilt University. Common events reported in product literature and postmarketing databases maintained by the FDA Adverse Event Reporting System include sexual dysfunction, weight changes, gastrointestinal symptoms, and sleep disturbances documented in reviews by editorial boards of journals such as The Lancet, The New England Journal of Medicine, and JAMA. Withdrawal or discontinuation syndrome has been described in cohort studies led by researchers at King's College Hospital and summarized in guidelines from American Academy of Child and Adolescent Psychiatry and Royal College of Psychiatrists. Rare but serious events such as serotonin syndrome and hyponatraemia were characterized in case reports from tertiary centers like Johns Hopkins Hospital and Cleveland Clinic and discussed in safety advisories from the European Medicines Agency.
Pharmacokinetic and pharmacodynamic interactions were evaluated in pharmacology units at University of California, San Diego and University of Michigan. Notable interactions involve other serotonergic agents referenced in clinical practice by specialists at Mayo Clinic and Mount Sinai, certain anticoagulants monitored in hematology services at Memorial Sloan Kettering Cancer Center, and CYP450 modulators with labeling influenced by advisory committees at the FDA and European Commission. Co-administration with monoamine oxidase inhibitors is contraindicated per warnings issued by regulatory bodies such as Health Canada and agencies advising on drug safety in Japan and Germany. Drug interaction compendia used in hospital formularies at institutions like Brigham and Women's Hospital list dose adjustments and monitoring strategies.
Paroxetine's mechanism as a selective serotonin reuptake inhibitor was delineated in biochemical studies from laboratories at Salk Institute, Max Planck Society affiliates, and university departments at Columbia University and Princeton University. Binding studies referenced work published by researchers connected to Rockefeller University and neurotransmitter assays performed in collaboration with institutes such as Karolinska Institutet. Pharmacokinetic parameters including absorption, hepatic metabolism predominantly via cytochrome P450 enzymes, and elimination were quantified in clinical pharmacology trials at centers like University of Oxford and reported to regulatory authorities including the European Medicines Agency. Structure–activity research referencing medicinal chemistry groups at MIT and ETH Zurich informed analog development and patent filings reviewed by patent offices like the United States Patent and Trademark Office.
Recommended dosing regimens were established through randomized controlled trials coordinated by clinical research units at Duke University Medical Center, University of Washington, and multinational study groups collaborating with agencies such as the National Institute of Mental Health. Initiation, titration, and maintenance dosing protocols are described in prescribing information distributed by manufacturers and summarized in formularies used at hospitals including Toronto General Hospital and St Thomas' Hospital. Pediatric, geriatric, and peripartum dosing considerations have been evaluated in studies from Children's Hospital of Philadelphia, Boston Children's Hospital, and tertiary maternity centers like Guy's and St Thomas' NHS Foundation Trust.
Regulatory history and legal actions related to Paxil have involved pharmaceutical companies litigated in courts such as the United States District Court for the Southern District of New York and regulatory scrutiny by agencies including the Food and Drug Administration and European Medicines Agency. Class-action suits, settlements, and regulatory warnings referenced filings in judicial districts overseen by courts like the United States Court of Appeals for the Ninth Circuit and legal analyses published by law faculties at Harvard Law School and Yale Law School. Labeling changes, boxed warnings, and risk-management communications were issued following reviews by advisory committees convened by institutions such as the FDA's advisory panels and national medicines agencies in countries including France, Italy, and Spain.
Category:Antidepressants